Clinical Trial

SLN12140 in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 4, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if drug SLN12140 works to treat Complement Inhibitor-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria in adults. It will also learn about the safety, pharmacokinetic characteristics, and dosing of drug SLN12140. The study is divided into four phases: screening period, core treatment period, extended dosing period, and follow-up period, and includes two cohorts (Cohorts 1-2), with each cohort enrolling at least 5 treatment-naïve adult PNH subjects for complement inhibitor therapy.
Trial Details
NCT Number NCT07387302
Lead Sponsor Linno Pharmaceuticals, Inc.
Conditions Paroxysmal Nocturnal Hemoglobinuria (PNH)
Enrollment 10 participants
Start Date 2026-02-10
Primary Completion 2026-07-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-04